摘要
目的探讨罗沙司他治疗肾性贫血患者的效果及对生活质量的影响。方法选取2021年9月至2023年1月邵阳市中心医院肾病内科收治的96例肾性贫血患者作为研究对象,按照随机抽签法分为参照组(48例)与研究组(48例),参照组采用促红细胞生成素联合蔗糖铁治疗,研究组采用罗沙司他治疗。比较两组患者的生活质量、贫血指标、铁代谢指标、不良反应发生率、蒙特利尔认知评估量表(MoCA)评分。结果用药前,两组患者的生活质量、贫血指标、铁代谢指标比较,差异无统计学意义(P>0.05);用药后,两组患者生活质量、贫血指标、铁代谢指标均高于本组用药前,研究组患者的生活质量、贫血指标、铁代谢指标均高于参照组,差异有统计学意义(P<0.05)。用药期间研究组患者的不良反应总发生率低于参照组,差异有统计学意义(P<0.05)。用药后,研究组患者的治疗总有效率高于参照组,差异有统计学意义(P<0.05)。用药前,两组患者的MoCA评分比较,差异无统计学意义(P>0.05);用药后,两组患者MoCA评分均高于本组用药前,研究组患者的MoCA评分高于参照组,差异有统计学意义(P<0.05)。结论罗沙司他治疗肾性贫血对患者生活质量的提升作用明确,贫血指标、铁代谢指标均在较短时间内改善,有利于患者病情的缓解,具有可行性。
Objective To investigate the effect of Roxadustat in the treatment of renal anemia and its influence on quality of life.Methods A total of 96 patients with renal anemia admitted to the Department of Nephrology,the Central Hospital of Shaoyang from September 2021 to January 2023 were selected as the research subjects,and they were divided into the reference group(48 cases)and the study group(48 cases)according to random drawing method.The reference group was treated with erythropoietin combined with iron sucrose,and the study group was treated with Roxadustat.The quality of life,anemia index,iron metabolism index,incidence of adverse reactions and Montreal cognitive assessment(MoCA)score were compared between the two groups.Results Before medication,there were no significant differences in quality of life,anemia indexes and iron metabolism indexes between two groups(P>0.05).After medication,the quality of life,anemia indexes and iron metabolism indexes of patients in two groups were higher than those before medication,and the quality of life,anemia indexes and iron metabolism indexes of patients in the study group were higher than those in the reference group,with statistical significances(P<0.05).The total incidence of adverse reactions in the study group was lower than that in the reference group,and the difference was statistically significant(P<0.05).After medication,the total effective rate of the study group was higher than that of the reference group,and the difference was statistically significant(P<0.05).Before medication,there were no significant differences in MoCA scores between the two groups(P>0.05).After medication,the MoCA scores of the two groups were higher than those before medication,and the MoCA score of the study group was higher than that of the reference group,with statistical significances(P<0.05).Conclusion Roxadustat can improve the quality of life of patients with renal anemia,and the indexes of anemia and iron metabolism can be improved in a short time,which is conducive to the remission of patients'disease.
作者
唐湘玲
TANG Xiangling(Department of Nephrology,the Central Hospital of Shaoyang,Hunan Province,Shaoyang 422000,China)
出处
《中国当代医药》
CAS
2024年第12期48-51,60,共5页
China Modern Medicine
关键词
罗沙司他
肾性贫血
效果
生活质量
影响
Roxadustat
Renal anemia
Effect
Quality of life
Influence
